Clinical Trial Update: Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating safety and efficacy of SelK2 on airway responses after allergen challenge in asthma and COPD; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SelK2 (SelK2)

Snippet

Sponsor: Tetherex Pharmaceuticals Corporation | Conditions: Asthma, Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED